syvn1 Antibody

What is SYVN1 and what are its primary cellular functions?

SYVN1 (also known as HRD1 or synoviolin) is an E3 ubiquitin-protein ligase located in the endoplasmic reticulum (ER) membrane. It functions as a critical component of the endoplasmic reticulum quality control (ERQC) system, also called ER-associated degradation (ERAD), which is involved in ubiquitin-dependent degradation of misfolded ER proteins . SYVN1 accepts ubiquitin specifically from endoplasmic reticulum-associated UBC7 E2 ligase and transfers it to substrates, promoting their degradation . Beyond protein quality control, SYVN1 protects cells from ER stress-induced apoptosis and has been identified as an anti-apoptotic factor implicated in arthropathy pathogenesis by promoting synovial hyperplasia . Recent research has also revealed its role in regulating ER shape and COPII export by mediating ubiquitination of atlastins (ATLs), particularly ATL1 .

What is the molecular structure and cellular localization of SYVN1?

SYVN1 is a multispanning RING-finger protein embedded in the ER membrane . The human SYVN1 protein consists of 617 amino acids with a calculated molecular weight of 68 kDa, though it is typically observed at 68-76 kDa in experimental conditions . It contains one ring-type zinc finger domain that is essential for its E3 ligase activity . SYVN1 is primarily localized to the endoplasmic reticulum membrane as a multi-pass membrane protein, positioning it perfectly for its role in ERAD and protein quality control . The protein is ubiquitously expressed in human tissues, with particularly high expression levels in liver and kidney . Notably, SYVN1 is up-regulated in synovial tissues from patients with rheumatoid arthritis, suggesting its pathological significance .

What are the different types of SYVN1 antibodies available for research?

Multiple types of SYVN1 antibodies are available for research purposes, varying in their target epitopes, host species, and applications. Polyclonal antibodies produced in rabbits are common, such as the 13473-1-AP antibody that targets the full SYVN1 protein and shows reactivity with human, mouse, and rat samples . C-terminal specific antibodies like AP2184a target the region between amino acids 586-617 of human SYVN1 . These antibodies differ in their optimal applications: some are particularly suited for Western blotting at dilutions of 1:1000-1:4000, while others work optimally for immunohistochemistry (1:50-1:500) or immunofluorescence (1:50-1:500) . The choice of antibody should be guided by the specific experimental requirements, target species, and intended application methodology.

What are the validated applications for SYVN1 antibodies and their optimal protocols?

SYVN1 antibodies have been validated for multiple research applications with specific optimal protocols:

Western Blotting (WB):

• Recommended dilutions range from 1:1000-1:4000, depending on the specific antibody

• Successfully detected in multiple cell lines including HEK-293, HeLa, HepG2, and tissues such as mouse kidney, ovary, pancreas, and stomach

• The observed molecular weight typically ranges from 68-76 kDa

Immunoprecipitation (IP):

• Optimal usage: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Successfully validated in mouse kidney tissue

• Can be used at 1:100 dilution with some antibody products

Immunohistochemistry (IHC):

• Recommended dilutions of 1:50-1:500

• Antigen retrieval with TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 can serve as an alternative

• Positive detection reported in human kidney tissue

Immunofluorescence (IF)/Immunocytochemistry (ICC):

• Optimal dilutions range from 1:50-1:500

• Successfully used in HepG2 cells

Each application requires proper sample preparation and optimization, as reactivity may vary depending on the specific antibody and experimental conditions.

How should researchers optimize SYVN1 antibody usage for detecting low abundance protein?

For detecting low abundance SYVN1 protein, researchers should implement several optimization strategies:

• Enrichment techniques: Utilize immunoprecipitation before Western blotting to concentrate the protein of interest. Using 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate has shown successful results in mouse kidney tissue .

• Signal amplification systems: For immunohistochemistry or immunofluorescence applications, implement tyramide signal amplification or other enhancement methods to increase detection sensitivity while maintaining the recommended dilution ranges (1:50-1:500) .

• Extended exposure times: For Western blotting, longer exposure times can help visualize weak signals, but this should be balanced against increased background.

• Sample selection: Focus on tissues known to have higher SYVN1 expression, such as liver and kidney, when establishing protocols .

• Antibody selection: Choose antibodies with demonstrated high sensitivity for endogenous protein detection, as indicated in antibody specifications .

• Buffer optimization: Adjust lysis conditions to ensure complete solubilization of the membrane-bound SYVN1 protein, using detergents appropriate for multi-pass membrane proteins.

• Blocking optimization: Test different blocking agents (BSA vs. milk) and concentrations to minimize background while preserving specific signal.

What controls should be included when using SYVN1 antibodies in experimental designs?

Robust experimental design with proper controls is essential for SYVN1 antibody research:

Positive controls:

• Cell lines with confirmed SYVN1 expression: HEK-293, HeLa, HepG2, MDA-MB-453s, NIH/3T3, and Raji cells

• Tissue samples with known expression: mouse kidney, ovary, pancreas, stomach, and rat stomach tissue

Negative controls:

• SYVN1 knockout or knockdown samples: Several publications have utilized SYVN1 KD/KO systems that can serve as negative controls

• Primary antibody omission: Include samples treated identically but without primary antibody

• Isotype controls: Include samples treated with non-specific rabbit IgG at equivalent concentrations

Loading and transfer controls:

• For Western blotting, include housekeeping protein detection (such as GAPDH, β-actin, or α-tubulin)

• For IP experiments, include IgG heavy and light chain detection to confirm successful antibody recovery

Specificity controls:

• Peptide competition assays using the immunogen peptide (for C-terminal antibodies, the peptide spanning amino acids 586-617 can be used)

• Validation across multiple techniques (e.g., confirming WB results with IF/IHC)

The inclusion of these controls helps ensure experimental validity and antibody specificity.

How can SYVN1 antibodies be used to investigate ER stress and ERAD pathways?

SYVN1 antibodies provide powerful tools for investigating ER stress and ERAD pathways through several advanced approaches:

• Stress-induced changes in SYVN1 expression: Researchers can quantify SYVN1 protein levels via Western blotting (1:1000-1:4000 dilution) under various ER stress conditions (tunicamycin, thapsigargin, DTT treatment) to establish temporal expression patterns .

• Subcellular localization studies: Immunofluorescence with SYVN1 antibodies (1:50-1:500 dilution) can be combined with other ER markers to monitor potential stress-induced relocalization within ER subdomains .

• SYVN1-substrate interactions: Co-immunoprecipitation using SYVN1 antibodies can identify novel substrate interactions during ER stress. This approach has been successfully used in at least 5 published studies .

• ERAD complex formation: SYVN1 antibodies can be used to co-immunoprecipitate and characterize components of dynamic ERAD complexes that form under different cellular conditions.

• Post-translational modification analysis: Immunoprecipitation with SYVN1 antibodies followed by mass spectrometry can reveal how SYVN1 itself is regulated through modifications during ER stress.

• Degradation kinetics: By combining cyclohexamide chase assays with SYVN1 antibody detection, researchers can assess how ERAD substrate degradation rates change under different conditions.

These approaches enable mechanistic insights into the role of SYVN1 in maintaining ER homeostasis during stress conditions.

What are the best approaches for studying SYVN1's role in disease models, particularly in rheumatoid arthritis?

Given SYVN1's up-regulation in synovial tissues from rheumatoid arthritis patients, several approaches can effectively investigate its pathological roles:

• Comparative expression analysis: Use immunohistochemistry (1:50-1:500 dilution) to quantitatively compare SYVN1 expression between normal and diseased synovial tissues . This approach can correlate expression levels with disease severity.

• Animal model studies: Implement SYVN1 antibodies in rodent arthritis models to track expression changes during disease progression and in response to therapeutic interventions.

• Synoviocyte culture systems: Apply immunofluorescence (1:50-1:500) to examine SYVN1 localization in primary synoviocytes from patients versus controls, particularly under inflammatory stimulation .

• Substrate identification in disease context: Use co-immunoprecipitation with SYVN1 antibodies in diseased versus normal tissues to identify differential substrate targeting that might contribute to pathogenesis.

• Therapeutic response monitoring: Implement SYVN1 antibody-based assays to assess how anti-rheumatic treatments affect SYVN1 levels and activity.

• Combined genetic approaches: Correlate SYVN1 expression data (using antibody-based detection) with genetic polymorphism data to identify susceptibility factors.

• Examination of post-translational regulation: Study ubiquitination patterns in diseased tissues using SYVN1 antibodies coupled with ubiquitin detection.

These methodologies can help elucidate SYVN1's contribution to synovial hyperplasia and identify potential therapeutic targets.

How can researchers effectively study the relationship between SYVN1 and atlastins in ER morphology regulation?

Recent findings have revealed SYVN1's role in regulating ER morphology through atlastin ubiquitination, particularly ATL1 . To investigate this relationship effectively:

• Co-localization studies: Implement dual immunofluorescence with SYVN1 (1:50-1:500) and atlastin antibodies to examine their spatial relationship within the ER network .

• Ubiquitination assays: Immunoprecipitate atlastins and probe for ubiquitination, or conversely, immunoprecipitate SYVN1 to identify associated atlastins and examine how this interaction changes under different conditions.

• ER morphology analysis: Combine SYVN1 knockdown/overexpression with high-resolution microscopy of the ER (using markers such as calnexin) to quantify changes in ER tubule formation, branching, and sheet structures.

• SYVN1 domain analysis: Use structure-function studies with domain-specific antibodies to determine which regions of SYVN1 are critical for atlastin interaction and ubiquitination.

• In vitro reconstitution assays: Develop cell-free systems using purified components to directly test SYVN1's ubiquitination activity on atlastins.

• Dynamic studies of ER remodeling: Implement live cell imaging with fluorescently tagged ER markers in cells with modified SYVN1 expression to observe real-time changes in ER morphology.

• COPII vesicle formation assays: Examine how the SYVN1-atlastin relationship affects COPII export using vesicle budding assays coupled with Western blotting detection of cargo proteins.

These approaches can help elucidate the molecular mechanisms by which SYVN1 contributes to ER morphological regulation through atlastin modification.

What are common issues in SYVN1 antibody applications and how can they be resolved?

Researchers frequently encounter several challenges when working with SYVN1 antibodies:

Multiple bands in Western blotting:

• Issue: Detection of multiple bands beyond the expected 68-76 kDa range

• Solutions: Optimize sample preparation with appropriate protease inhibitors; adjust reducing conditions; verify specificity with knockdown controls; test alternative antibodies targeting different epitopes

Weak or no signal:

• Issue: Insufficient detection despite known expression

• Solutions: Reduce antibody dilution within recommended ranges; increase protein loading; optimize antigen retrieval for IHC (try both TE buffer pH 9.0 and citrate buffer pH 6.0) ; extend incubation times; use fresh antibody aliquots

High background:

• Issue: Non-specific staining or signal

• Solutions: Increase blocking duration; test alternative blocking agents; optimize antibody concentration; include additional washing steps; for IHC/IF, test specialized blocking for endogenous peroxidase or biotin

Inconsistent immunoprecipitation:

• Issue: Variable pull-down efficiency

• Solutions: Adjust antibody amounts (0.5-4.0 μg per 1.0-3.0 mg lysate) ; modify lysis conditions to better solubilize membrane proteins; pre-clear lysates thoroughly; optimize bead type and binding conditions

Cell type variability:

• Issue: Inconsistent results across cell types

• Solutions: Validate using positive control cell lines (HEK-293, HeLa, HepG2) ; adjust protocols for specific cell types; consider endogenous expression levels when interpreting results

Careful optimization and inclusion of appropriate controls can address most technical challenges.

What considerations should researchers keep in mind when comparing results from different SYVN1 antibodies?

When utilizing or comparing results from different SYVN1 antibodies, researchers should consider:

• Epitope differences: Antibodies targeting different regions (e.g., C-terminal region 586-617 aa vs. full-length protein) may yield varying results due to epitope accessibility in different experimental conditions or protein conformations .

• Clonality variations: Polyclonal antibodies may recognize multiple epitopes and show broader reactivity but potentially more background, while monoclonal antibodies offer higher specificity for a single epitope but may be more sensitive to epitope masking.

• Host species considerations: All reviewed antibodies are rabbit-derived , but when combining with other antibodies in multiplexed experiments, host species compatibility must be considered.

• Species cross-reactivity differences: Some antibodies react with human, mouse, and rat samples , while others only recognize human and mouse or human and monkey . This impacts comparative studies across species.

• Application-specific optimization: Optimal dilutions vary significantly between applications:

  Application	Dilution Range	Notes
  Western Blot	1:1000-1:4000	May need optimization for specific lysate types
  Immunohistochemistry	1:50-1:500	Requires appropriate antigen retrieval
  Immunofluorescence	1:50-1:500	Cell type may affect optimal dilution
  Immunoprecipitation	0.5-4.0 μg / 1-3 mg lysate	Protein amount affects efficiency

• Validation status: Consider the extent of validation for each antibody. For example, antibody 13473-1-AP has been cited in numerous publications, including 64 for Western blotting, 3 for IHC, 8 for IF, 6 for IP, and 5 for Co-IP .

• Molecular weight detection: While calculated molecular weight is 68 kDa, observed weights range from 68-76 kDa , so apparent size differences between antibodies may reflect detection of different post-translational modifications.

What advanced experimental designs can help resolve conflicting data when studying SYVN1 function?

When conflicting data emerges in SYVN1 functional studies, several advanced experimental approaches can help resolve discrepancies:

• Multi-antibody validation: Employ multiple antibodies targeting different SYVN1 epitopes to confirm findings. This strategy can rule out antibody-specific artifacts by demonstrating consistent results across different detection reagents .

• Genetic validation approaches:

  • CRISPR/Cas9 knockout of SYVN1 as definitive negative control

  • Rescue experiments with wild-type vs. mutant SYVN1 expression in knockout backgrounds

  • siRNA/shRNA-mediated knockdown with multiple target sequences to control for off-target effects

• Domain-specific functional analysis:

  • Structure-function studies using truncated or point-mutated SYVN1 constructs

  • Selective disruption of interactions with specific partners to dissect mechanisms

• Temporal analyses:

  • Time-course experiments to distinguish primary from secondary effects

  • Inducible expression/depletion systems to control timing of SYVN1 modulation

• Orthogonal technical approaches:

  • Complement antibody-based detection with non-antibody methods (e.g., mass spectrometry)

  • Functional readouts that don't rely on direct SYVN1 detection (e.g., ER stress markers, substrate half-life)

• Physiological context considerations:

  • Test hypotheses in multiple cell types relevant to the biological question

  • Validate findings in primary cells or tissues as well as cell lines

  • Consider stress conditions that might trigger context-specific functions

• Quantitative controls:

  • Include dose-response relationships

  • Implement internal standards for normalization

  • Use statistical approaches appropriate for the experimental design

By implementing these approaches, researchers can build stronger evidence for specific SYVN1 functions and resolve apparent contradictions in the literature.

What emerging research areas show promise for SYVN1 antibody applications?

Several emerging research areas present exciting opportunities for SYVN1 antibody applications:

• Single-cell analysis of SYVN1 expression: Applying SYVN1 antibodies in single-cell proteomics and imaging mass cytometry to understand cell-to-cell variability in expression and function, particularly in heterogeneous tissues like synovium in rheumatoid arthritis .

• Super-resolution microscopy: Implementing SYVN1 antibodies in techniques like STORM, PALM, or expansion microscopy to visualize precise ER subdomain localization and dynamic interactions with ERAD components at nanoscale resolution.

• In situ proximity labeling: Combining SYVN1 antibodies with enzyme-mediated proximity labeling methods (BioID, APEX) to identify spatial proteomes surrounding SYVN1 under different cellular conditions.

• Organoid and 3D culture systems: Applying immunofluorescence protocols (1:50-1:500 dilution) to study SYVN1 in more physiologically relevant 3D culture models of liver, kidney, and synovial tissues .

• Tissue-specific conditional knockout validation: Using SYVN1 antibodies to validate tissue-specific knockout models and correlate expression with phenotypic changes across development and disease progression.

• Extracellular vesicle analysis: Investigating potential SYVN1 presence in extracellular vesicles as biomarkers for ER stress and inflammatory conditions.

• Post-translational modification mapping: Developing modification-specific antibodies to study how SYVN1 activity is regulated through phosphorylation, ubiquitination, or other modifications.

These emerging approaches could significantly advance our understanding of SYVN1 biology and pathological mechanisms.

How might advances in antibody technology improve SYVN1 research capabilities?

Emerging antibody technologies promise to enhance SYVN1 research capabilities:

• Recombinant antibody production: Moving beyond traditional polyclonal antibodies to recombinant monoclonal antibodies with defined epitopes will improve reproducibility across laboratories and applications.

• Nanobodies and single-domain antibodies: Developing smaller antibody fragments against SYVN1 could improve penetration into complex tissues and access to epitopes in the transmembrane regions that are challenging for conventional antibodies.

• Bispecific antibodies: Creating bispecific antibodies that simultaneously target SYVN1 and its interaction partners could enable direct visualization of protein complexes in situ.

• Conditionally stable antibody fragments: Implementing antibody-based sensors that respond to SYVN1 activity or conformation changes could provide dynamic readouts of function rather than just expression levels.

• Intrabodies and chromobodies: Developing antibody fragments that function in the intracellular environment would allow live-cell imaging of endogenous SYVN1 dynamics.

• Epitope-specific degraders: Adapting SYVN1 antibodies into targeted protein degradation technologies could provide new tools for acute protein depletion experiments.

• Spatially-resolved antibody detection: Implementing in situ sequencing and spatial transcriptomics approaches combined with SYVN1 antibody detection to correlate protein expression with local transcriptional signatures.

These technological advances could significantly expand our ability to study SYVN1's diverse functions in cellular homeostasis and disease.

What are the key unanswered questions in SYVN1 biology that antibody-based research might address?

Several critical questions in SYVN1 biology remain unanswered and could be addressed through strategic application of antibody-based research:

Addressing these questions through antibody-based approaches would significantly advance our understanding of this multifunctional protein and potentially reveal new therapeutic opportunities.